Veracyte, a company providing genomic solutions in molecular cytology, has announced that Palmetto GBA posted a draft local coverage determination (LCD) for their Percepta Bronchial Genomic Classifier. The move follows the posting by Noridian Health on September 8, 2016.

Veracyte (NASDAQ:VCYT), a company providing genomic solutions in molecular cytology, has announced that Palmetto GBA posted a draft local coverage determination (LCD) for the Percepta Bronchial Genomic Classifier. The move follows the posting by Noridian Health on September 8, 2016.
As quoted in the press release:

The Percepta classifier is a genomic test designed for use in lung cancer diagnosis. The test is supported by multiple published studies demonstrating its ability to make lung cancer screening and diagnosis more accurate and safe by reducing unnecessary surgeries on suspicious lung nodules found on computed tomography (CT) scans.

According to Veracyte’s CEO, Bonni Anderson:

“We are moving quickly toward securing draft Percepta LCDs from all four MolDx Program participants. We appreciate Palmetto GBA’s vision in creating and administering this program, which establishes transparency in the coverage assessment process, and thereby facilitates patient and physician access to important innovations in the genomic testing field.”

Read the full press release here.